09:12 AM EST, 12/19/2024 (MT Newswires) -- Mainz Biomed ( MYNZ ) said Thursday it partnered with Quest Diagnostics ( DGX ) to support the commercialization of its NextGen screening test for colorectal cancer.

Under the agreement, the company said Quest will provide clinical trial laboratory services for its clinical trial involving about 15,000 participants across 150 US sites, adding that the study will generate data for FDA validation of the NextGen test.

The medical test maker also said it would offer Quest semi-exclusive rights to provide testing services using the ColoAlert kit for 18 months, contingent on FDA approval.

ColoAlert test is a stool-based test to detect colorectal cancer tumor DNA to help identify colorectal cancer in its early stages.